secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105027
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight Q2 revenue $33.6M (-4% YoY); net loss $(11.8)M; reaffirms FY2025 guidance
--------------------------------------------------------------------------------

- Total revenue $33.6M, down 4% from $34.9M in Q2 2024; LAL units up 13%, LDD units down 49%.
- Net loss $(11.8)M ($(0.29)/share) vs $(6.1)M loss a year ago; adjusted net loss $(3.2)M.
- Installed LDD base grew 34% to 1,084 units; FDA approved expanded LAL diopter range to -2.0 to +3.0.
- Launched Light Adjustable Lens system in South Korea and Singapore; commercial team realigned.
- Reaffirmed FY2025 revenue guidance $120M-$130M, gross margin 72%-74%, opex $145M-$155M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017025105027/0000950170-25-105027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017025105027/rxst-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer